Coherus Oncology (CHRS) Other Operating Expenses (2019 - 2026)

Coherus Oncology has disclosed Other Operating Expenses across 8 years of filings, most recently posting $4.2 million for Q2 2026.

• In Q2 2026, Other Operating Expenses rose 24.95% year-over-year to $4.2 million; the TTM figure through Jun 2026 stood at $15.8 million (up 37.26% YoY), while the FY2025 annual figure was $13.8 million, up 58.29% from the prior year.
• Other Operating Expenses came in at $4.2 million for Q2 2026 at Coherus Oncology, up from $3.8 million in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $84.6 million in Q4 2023 to a low of $1.4 million in Q1 2024.
• Average Other Operating Expenses over 5 years is $14.4 million, with a median of $4.1 million recorded in 2025.
• Year-over-year, Other Operating Expenses soared 495.46% in 2023 and plunged 96.75% in 2024.
• Over 5 years, Other Operating Expenses stood at $14.2 million in 2022, then soared by 495.46% to $84.6 million in 2023, then sank by 96.75% to $2.8 million in 2024, then jumped by 47.09% to $4.0 million in 2025, then rose by 4.87% to $4.2 million in 2026.
• Per Business Quant data, the three most recent Other Operating Expenses figures were $4.2 million in Q2 2026, $3.8 million in Q1 2026, and $4.0 million in Q4 2025.